key: cord-0701421-scwy859p authors: Chappuis, G. title: Control of canine distemper date: 1995-05-31 journal: Veterinary Microbiology DOI: 10.1016/0378-1135(95)00028-9 sha: c5b89811fed3ea7f07b4fcf09b46bddac9358b29 doc_id: 701421 cord_uid: scwy859p Abstract Control of canine distemper can realistically only be achieved by the use of vaccination. The types of vaccine in current use are described, together with some of the problems encountered such as interference by maternal antibodies, and usage in species other than dogs. Modified live viral vaccines, as used for more than thirty years, have proved very effective. Nevertheless there is scope for some improvement in vaccine efficacy and recent developments in genetic recombinant methods are described. The only practicable and effective measure to control canine distemper is, at present, immunization by vaccination, even if classical hygienic measures can be applied in parallel. In 1966, R. McClelland and J.H. Gillespie wrote: "A great deal could be written about immunization against canine distemper, and much has been said in the past. With our present knowledge and testing procedures, there is less need for words because the approach to successful protection is relatively straightforward and simple" (McClelland and Gillespie, 1966) . Active immunity against canine distemper in dogs can be achieved by the use of various types of vaccines. Active immunization has been practised since Puntoni ( 1923) described the use of formaldehyde-inactivated canine distemper virus (CDV) -infected dog brain tissue. These early vaccines proved incapable of controlling the disease. Active immunization became very successful after live attenuated vaccines became available: ferret-passaged modified vaccine, modified hen egg virus vaccine (Haig, 1956) , modified cell culture virus vaccines (Rockborn, 1959) , heterotypic measles vaccine, and combined vaccines. Purified vaccines (Norrby et al., 1986) and ISCOM vaccines (de Vries et al., 1988) prepared over the past few years remain at an experimental stage. At present, modified live virus (MLV) vaccines are used on a large scale: in 1992 approximately 27.5 X lo6 doses of vaccine were used in the U.S.A. for a population of 53 X lo6 dogs, while in France in 1993,4 X lo6 doses were used for a population of 9.9 X lo6 dogs. Vaccines against distemper are now supplied only in freeze-dried form and are combined with other components such as adenovirus, parvovirus, and parainfluenza type 2 virus, and, sometimes, with rabies virus, coronavirus and Leptospira. The modified live CDV vaccines available today are either of avian egg origin (Onderstepoort strain) or canine cell culture adaptations (Rockbom strain) . Both these strains enable the preparation of very effective vaccines. From the regulatory viewpoint, it is interesting to compare the requirements of European authorities with those of America. The European Pharmacopoeia (European Council) monograph "Vaccinum morbi carrei vivum cryodessicatum pro cane" [Freeze-dried Canine Distemper Live Vaccine] mentions the essential criteria: safety of master seed virus, safety of every batch, potency. These specific requirements have been emphasized by the more recent regulations governing the registration of products in the European Union (Anon., 1992) . In the United States of America, the Code of Federal Regulations presents two monographs related to canine distemper vaccine, one concerning a ferret avirulent strain (9 CFR 113-306)) and the other one concerning a ferret virulent strain (9 CFR 113-307). These monographs are very complete and more precise than the European monograph. The intrinsic properties of vaccines containing a distemper component are critical for vaccine performance. Although industrial scale culture of the virus on cell systems does not raise any special problems, the storage and the heat-stability of the freeze-dried virus remains delicate. The producer therefore has to find a formula for the stabilizer to obtain the best shelf-life for the product. In combined vaccines, the distemper component is always the least heat-stable (by comparison with adenovirus and parvovirus components). Both methods of adaptation result in very effective vaccines (CDV Onderstepoort (CDVo) , CDV Rockbom ( CDVR) ) which induce immunity in susceptible dogs that lasts for at least one year. If the routes of vaccination are compared in susceptible dogs immunized with a single dose of MLV-CDVo vaccine ( 104.6 CCIDSO/dose), we can observe a better seroneutralizing antibody response at 21 days post-vaccination by the intravenous and intramuscular routes than by the subcutaneous route (2.6 log,, by IV route, 2.2 log,, by IM route, and 1.8 log,, by SC route). With the same vaccine, the onset of protection was assessed after subcutaneous or intravenous vaccination of groups of dogs. They were subsequently challenged by intracerebral inoculation of the virulent Snyder Hill virus at 1, 2, 3, 4, 5 or 6 days after a single injection of vaccine. Complete protection was obtained within 48 hours following intravenous vaccination and within 5 days following subcutaneous vaccination (Chappuis and Terre, 1973a; Chappuis et al., 1973) . The intravenous route is not usually recommended for vaccination. It could, if necessary, be used in case of emergency (contamination of a puppy at the time of primary vaccination). The preferred route of administration, and that used routinely, is intramuscular. It should also be mentioned that immunization is possible by the oral and oculo-nasal routes (Chappuis and Terre, 1973b) . A comparison of antibody responses, by intramuscular and subcutaneous routes, for both CDVo and CDVn vaccine strains at equivalent titres, confirms the superiority of the intramuscular route over the subcutaneous, with the CDVR strain inducing a higher antibody response (Table 1) . However, despite a less intense response for the CDVo strain, all dogs were seropositive and totally protected against virulent challenge one year after a single vaccination. In the case of multiple combined vaccines, and despite satisfactory compatibility tests, we have often observed that the CDV antibody kinetics were always poorer (for a given route of administration and an identical vaccinal titre) in a group of dogs receiving the combined vaccine than in a group receiving only the distemper component. This was not the case for the adenovirus and parvovirus components. Nevertheless, complete protection against a distemper challenge was still observed in both groups of dogs. Besides the intrinsic qualities of a vaccine, the presence of residual maternally-derived antibodies can be a problem at the time of primary vaccination. This is not a new problem, as shown by the historical work of Gillespie ( 1966) who establisheda nomographpredicting the earliest age at which to vaccinate puppies based on the antibody titre of the bitch, and on the calculated half life of maternally-derived antibody titres. The decay rate of these passive antibodies is proportional to the growth rate of dogs (Fig. 1) . Dogs belonging to rapid-growth breeds "eliminate" their maternally-derived antibodies more quickly and therefore become more rapidly susceptible to the disease and receptive to immunization. Thus maternally-derived antibodies, whilst beneficial for early protection against the infection, disturb the vaccinal immunization. It could be postulated, as has been shown in the case of canine parvovirus (Burtonboy et al., 1991) , that vaccines with high titres are likely to be more effective in the presence of residual maternally-derived antibodies. Recent evidence for CDV vaccine supports this (Chalmers and Baxendale, 1994) . Because the persistence of maternal antibodies is a well-known cause of vaccine failure, the recommended primary vaccination consists of two consecutive injections. The second should be given to puppies around 12-14 weeks of age, by when a complete disappearance of passive immunity is expected and the vaccine should be completely effective (Chappuis et al., 1974; Terre et al., 1978) . For an active booster effect, it is possible to increase the level of preexisting active antibodies by revaccination. In our experiments a booster effect was observed in dogs with existing seroneutralizing antibody tines up to 1: 100. The booster effect is inversely related to the level of previous seroneutralizing antibody titre. In a kennel, booster vaccination can establish a homogeneous immune status among the bitches thus simplifying the vaccination programme for the litters ( Michel et al., 197 1) . Heterotypic (measles) virus vaccination has been one approach to overcoming neutralization by maternally-derived antibody. Measles virus (MV) is not neutralized by CDV antibodies. MV induces a clinical protection against CDV (Baker, 1970) . The use of MV vaccines was originally recommended for puppies aged 2-4 weeks, although it was not very successful in field conditions. Afterwards, a combination of attenuated MV and CDV was applied in puppies aged 6 to 10 weeks. This is acceptable for the first generation: however puppies vaccinated and boosted with this vaccine will produce antibodies against both MV and CDV, and subsequently as bitches will transfer antibodies of both specificities to their litters. Although CDV vaccines are safe and efficacious, adverse reactions can occur (Tizard, 1990; Brooks, 199 1) . Adverse reactions are often a complex interaction between the animal, the vaccine (which contains more and more antigens) and the environment which includes the veterinarian. In the investigation of any adverse reaction, all three components need to be examined. Modified live CDV vaccine multiplies in dogs causing transient immunosuppression and thrombocytopenia (Straw, 1978) . The reversion to virulence of Rockbom strain was demonstrated by Appel ( 1978) after serial passages in dogs. Encephalitis in dogs with a batch of CDV vaccine was observed by Comwell et al. ( 1988) . Interactions between CDV and adenovirus MLV vaccines can induce the suppression of lymphocyte responsiveness (Phillips et al., 1989) . Canine parvovirus infection potentiates canine distemper encephalitis attributable to modified live virus vaccine (Krakowka et al., 1982) . A parallel can be drawn between the latter observation and epidemiological observations over the last fifteen years. In fact, before the emergence of canine parvovirus, distemper had largely disappeared from veterinary practice, whereas since 1980, it has not been exceptional to observe distemper, sometimes in the form of epidemics, and even in urban dog populations (Blixenkrone-Moller et al., 1993) . This can but lead us to continue promoting vaccination with the existing vaccines, even if improvements can still be made. The vaccination of mustelids has been widely and successfully used in colonies. The MLV "ferret avirulent' ' strains, strain Onderstepoort for instance, are fully effective. The doses used represent one tenth of the dose for dogs. The routes of administration are subcutaneous, intramuscular and aerosol-spraying routes. Concerning the latter route, the adjustment of the dose volume is difficult and generally induces a lesser degree of immunization. It is recommended to take great care with vaccination of captive wild carnivores (Montali et al., 1983) . In principle, modified live vaccines should be avoided unless they have been shown to be totally safe for the species involved. If not, the preparation of inactivated vaccines should be considered. This was carried out by Appel and colleagues to save Mustela nigripes (black footed ferret) from complete disappearance (Carpenter et al., 1976 ). An adjuvanted inactivated ISCOM vaccine was successfully used in seals in 1989. Its immunogenicity was demonstrated against both the PDVr and PDV, viral strains (Osterhaus et al., 1989; Visser et al., 1992) . The vaccines used at present have provided an adequate solution for the immunization of dogs against CDV over more than thirty years. If there is still scope for improving the Total protection 2 + no signs 5 --f CDV disease 3 + died epidemiological situation in the canine species by enhancing preventive medicine, then the principal tools used, the vaccines, could also be improved. It has been indicated above that attenuated vaccine strains have certain deficiencies as regards heat stability and specific safety for some immunodeficient puppies and for other wild carnivores. Furthermore, safer routes of administration than injection could be used, the oral route for instance, and more practical and more effective vaccination schedules could be developed, above all for combined vaccinations. One of the most promising approaches is that offered by new technologies, using recombinant vaccines. A variety of viruses have been used as carriers for heterologous genes inserted by recombinant DNA technology. Vaccinia virus has been most commonly used as a vector for foreign genes (Panicali and Paoletti, 1972) . Studies have been undertaken in recent years to evaluate the safety and suitability of vaccinia virus as an eukaryotic expression vector in different mammalian species including dogs ( Appel, 1988; Pastoret et al., 1992) . Because of its safety, efficacy, and heat-stability, the vaccinia-rabies recombinant offers an excellent alternative to the attenuated strains of rabies virus currently used in the field to achieve the immunization of foxes (Kieny et al., 1984) . The potency of the same recombinant ( vVRG) was demonstrated in the canine species (Chappuis et al., 1994) . Experimental vaccines prepared from poxvitus recombinants (vaccinia, fowl pox or canary pox) including genes F and H of measles virus and of canine distemper virus have been tested in mice (Wild et al., 1993) but mainly in dogs. Their total safety and excellent immunogenicity were demonstrated during vaccination/challenge trials (Tartaglia et al., 1972) . As an example, Table 2 shows recent results obtained in our laboratory using a CDV-Canary pox recombinant. The four vaccinated puppies received 2 injections of recombinant at a 3-week interval ( 10' PFU/dose) . Challenged six weeks after the first injection, they were totally protected after having developed an antibody response. Out of the seven challenge control puppies, five developed distemper and three died. These results are therefore highly encouraging and support other results obtained with other similar recombinants. This new approach offers the prospect of positive developments and further improvements in the control of canine distemper. I would like, as a conclusion, to quote from Max Appel ( 1987) : "Eradication of CDV, as has been suggested for the related measles virus in man, may be desirable but is not possible. Many species of wild carnivores are susceptible to CDV and they represent a constant source of infection together with diseased dogs that have not been properly vaccinated." Commission Directive 92/18/EEC of 20 Reversion to virulence of attenuated canine distemper virus in vivo and in vitro Canine distemper virus (Chap. 13). Virus Infections of Carnivores Immune response to vaccinia virus and recombinant virus products in dogs Measles vaccine for protection of dogs against canine distemper Studies on manifestations of canine distemper virus infection in an urban population Adverse reactions to canine and feline vaccines Performance of high titre attenuated canine parvovirus vaccine in pups with maternally derived antibody Fatal vaccine-induced cdv infection in blackfooted ferrets A comparison of canine distemper vaccine and measles vaccine for the prevention of canine distemper in young puppies Immunisation contre la Maladie de Car& et la Maladie de Rubarth. II -Installation Precoce de 1'ImmunitC Immunisation contre la Maladie de Carre et la Maladie de Rubarth. III -Voie Oculonasale Immunisation contre la maladie de Carre et la maladie de Rubarth. I -La Serovaccination Immunisation contre la Maladie de Cane et la Maladie de Rubarth. IV -Calendrier de Vaccination Dog Rabies Vaccination. The Use of Recombinant Poxvirus by Oral and Parenteral Route Encephalitis in dogs associated with a batch of canine distemper vaccine Canine distemper virus ISCOMs but not MV-ISCOMs, protect dogs against CDV infection The significance of passive immunity and the biological tests used in the study of distemper Canine distemper immunization with avianised virus Expression of Rabies Virus Glycoprotein from a Recombinant Vaccinia Virus Canine Parvovirus Infection Potentiates Canine Distemper Encephalitis Attributable to MLV-Vaccine Canine Immunization. The Cornell Vet Vaccinations associees du chien. Comparaison entre vaccinations successives et vaccinations simultanees Clinical trial with canine distemper vaccines in exotic animals Protection against canine distemper virus in dogs after immunization with isolated fusion protein Seal vaccination success Construction of Poxviruses as Cloning Vectors: Insertion of the Thymidine Kinase Gene from Herpes Simplex Virus into the DNA of Infections Vaccinia Virus Development and deliberate release of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies Effects of vaccines on the canine immune system Saggio di vaccinazione anticimurossa preventiva eseguita per mezzo de1 virus specifico Decrease in platelet count after vaccination with distemper-hepatitis (DH) vaccine Novel poxvirus strains as research tools and vaccine vectors Calendrier de vaccination du chien Risks associated with use of live vaccines Canine distemper virus ISCOMs induce protection in harbour seals (Phocu uitulina) against phocid distemper but still allow subsequent infection with Phocid Distemper Virus-l. Vaccine Vaccination of mice against canine distemper virus induced encephalitis with vaccinia virus recombinants encoding measles or canine distemper antigens